Larissa Monteiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Larissa Monteiro has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ailton Melo
Universidade Federal da Bahia
5 shared publications Adelmir Souza-Machado
Health Sciences Institute, Federal University of Bahia, Brazil
2 shared publicationsA. Souza-Machado
Health Sciences Institute, Federal University of Bahia, Brazil
1 shared publication- Ana Caline Nóbrega
Universidade Federal da Bahia, Brasil
1 shared publication - Anna Clara Mota Duque
Postgraduate program in Medicine and Health, Federal University of Bahia, Brazil
1 shared publication - Bernardo Rodrigues
University of Connecticut
1 shared publication
Latest Publications
- 1 August 2021
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 207, 106722
Hemisphere stroke: impact on the semantic lexical aspects of language
- 1 August 2021
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 207, 106722
Hemisphere stroke: impact on the semantic lexical aspects of language
- Open Access
- 5 December 2014
- Published by MDPI AG in Neurology International
- Vol. 6 (4) , 70-73
Botulinum Toxin Type A for Cephalic Cutaneous Allodynia in Chronic Migraine: A Randomized, Double-Blinded, Placebo-Controlled Trial
Cephalic allodynia (CA) can be observed in 50-70% of patients with chronic migraine (CM). The aim of this trial was to assess the efficacy of botulinum toxin type A (Botx-A) in the treatment of CA associated with CM. In this placebo-controlled trial, patients were randomized either into Botx-A or 0.9% saline injections and efficacy measures were assessed every 4 weeks for 3 months. Efficacy endpoints were number of migraine episodes associated with CA, changes from baseline in visual analogical scale scores for pain (VAS) and frequency of common analgesics use for migraine. A total of 38 subjects were randomized to saline (n=18) or Botx-A (n=20). There were no significant differences in baseline between active intervention or placebo groups regarding mean age, number of headache episodes [mean 12.1 (9.22) and 17.00 (9.69) respectively; P=0.12], pain severity as measured by the VAS or frequency of analgesic use for headache episodes. Efficacy analysis showed that Botx-A injections led to an important decrease from baseline in the mean migraine episodes associated with CA after 12 weeks (5.20 versus 11.17; P=0.01). Also, VAS scores and frequency of analgesics use for headache were significantly reduced in the Botx-A group. This study suggests that Botx-A injections are superior to saline in the treatment of CA associated with CM, with mild self limited side effects.
- 5 December 2014
- Published by MDPI AG in Neurology International
- Vol. 6 (4) , 70-73
Open AccessBotulinum Toxin Type A for Cephalic Cutaneous Allodynia in Chronic Migraine: A Randomized, Double-Blinded, Placebo-Controlled Trial
Cephalic allodynia (CA) can be observed in 50-70% of patients with chronic migraine (CM). The aim of this trial was to assess the efficacy of botulinum toxin type A (Botx-A) in the treatment of CA associated with CM. In this placebo-controlled trial, patients were randomized either into Botx-A or 0.9% saline injections and efficacy measures were assessed every 4 weeks for 3 months. Efficacy endpoints were number of migraine episodes associated with CA, changes from baseline in visual analogical scale scores for pain (VAS) and frequency of common analgesics use for migraine. A total of 38 subjects were randomized to saline (n=18) or Botx-A (n=20). There were no significant differences in baseline between active intervention or placebo groups regarding mean age, number of headache episodes [mean 12.1 (9.22) and 17.00 (9.69) respectively; P=0.12], pain severity as measured by the VAS or frequency of analgesic use for headache episodes. Efficacy analysis showed that Botx-A injections led to an important decrease from baseline in the mean migraine episodes associated with CA after 12 weeks (5.20 versus 11.17; P=0.01). Also, VAS scores and frequency of analgesics use for headache were significantly reduced in the Botx-A group. This study suggests that Botx-A injections are superior to saline in the treatment of CA associated with CM, with mild self limited side effects.
- 1 April 2014
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 339 (1-2) , 149-152
Swallowing impairment and pulmonary dysfunction in Parkinson's disease: The silent threats
- 1 April 2014
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 339 (1-2) , 149-152
Swallowing impairment and pulmonary dysfunction in Parkinson's disease: The silent threats
- 1 May 2012
- Published by Elsevier in Clinical Therapeutics
- Vol. 34 (5) , 1049-1055
The Effect of Levodopa on Pulmonary Function in Parkinson's Disease: A Systematic Review and Meta-Analysis
- 1 May 2012
- Published by Elsevier in Clinical Therapeutics
- Vol. 34 (5) , 1049-1055
The Effect of Levodopa on Pulmonary Function in Parkinson's Disease: A Systematic Review and Meta-Analysis
- 3 December 2010
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 123 (1) , 1-7
Association between allergies and multiple sclerosis: a systematic review and meta-analysis
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system that expresses a typical type 1 immune response (Th1). Allergies, on the other hand, present with high levels of type 2 (Th2) cytokines. Some authors observed that Th1 and Th2 diseases could coexist in the same subject. Besides its biological plausibility, the association between MS and allergies remains controversial. The aim of this systematic review and meta-analysis was to determine if there is an association between allergic diseases and MS. All clinical and epidemiological studies on patients with MS published up to July 2009, that assessed the association between allergic diseases and MS were reviewed. A total of 1010 articles were retrieved from search, and ten epidemiological studies were included in the analysis. The results showed that there is no evidence supporting an association between allergic diseases (OR: 0.91; CI 95%: 0.68-1.23), asthma (OR: 0.83; CI 95%: 0.48-1.44), allergic rhinitis (OR: 0.81; CI 95%: 0.59-1.12), eczema (OR: 0.93; CI 95%: 0.71-1.23) and MS. Additional prospective studies in this field might help to elucidate the nature of these associations.
- 3 December 2010
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 123 (1) , 1-7
Association between allergies and multiple sclerosis: a systematic review and meta-analysis
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system that expresses a typical type 1 immune response (Th1). Allergies, on the other hand, present with high levels of type 2 (Th2) cytokines. Some authors observed that Th1 and Th2 diseases could coexist in the same subject. Besides its biological plausibility, the association between MS and allergies remains controversial. The aim of this systematic review and meta-analysis was to determine if there is an association between allergic diseases and MS. All clinical and epidemiological studies on patients with MS published up to July 2009, that assessed the association between allergic diseases and MS were reviewed. A total of 1010 articles were retrieved from search, and ten epidemiological studies were included in the analysis. The results showed that there is no evidence supporting an association between allergic diseases (OR: 0.91; CI 95%: 0.68-1.23), asthma (OR: 0.83; CI 95%: 0.48-1.44), allergic rhinitis (OR: 0.81; CI 95%: 0.59-1.12), eczema (OR: 0.93; CI 95%: 0.71-1.23) and MS. Additional prospective studies in this field might help to elucidate the nature of these associations.